TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29706442

Group type: EXPERIMENTAL
Intervention: Functional stretching exercises, 3 times a week for 4 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Functional stretching exercises
Number of subjects: 45
Study: 27387325

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg once daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Doxorubicin 75 mg/m² for six cycles
Number of subjects: 120
Study: 24664649

Group type: EXPERIMENTAL
Intervention: Nurse-initiated treatment
Number of subjects: 245

Group type: COMPARATOR
Intervention: Physician-initiated treatment
Number of subjects: 245
Study: 22151696

Group type: EXPERIMENTAL
Intervention: Major depression
Number of subjects: 5869
Study: 20071644

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (2 g purified EPA/DHA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 34
Study: 18033153

Group type: EXPERIMENTAL
Intervention: Atomoxetine (Strattera)
Number of subjects: 3000
Study: 15902529

Group type: EXPERIMENTAL
Intervention: Sputum Gram stain, culture, and detection of pneumococcal antigen
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Urinary pneumococcal antigen test
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscopy
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Combination of Gram stain, culture, and detection of pneumococcal antigen
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Testing of urine for pneumococcal antigen
Number of subjects: 262
Study: 12154113

Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Acute ascorbic acid infusion
Number of subjects: 48
Study: 9926739

Group type: EXPERIMENTAL
Intervention: Ticarcillin/clavulanate 3.1 g every 6 hours
Number of subjects: 137

Group type: COMPARATOR
Intervention: Imipenem/cilistatin 500 mg every 6 hours
Number of subjects: 137
Study: 8780327

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrophysiologic Study (EPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Holter monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium channel blocking drugs
Number of subjects: 0
Study: 1937843

Group type: EXPERIMENTAL
Intervention: Platelet concentrates from AS-104
Number of subjects: 115

Group type: COMPARATOR
Intervention: Platelet concentrates from CS-3000
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Platelet concentrates from AS-104 stored in teflon bags
Number of subjects: 115

Group type: COMPARATOR
Intervention: Platelet concentrates from CS-3000 stored in polyolefine bags
Number of subjects: 115
Study: 7082525

Group type: EXPERIMENTAL
Intervention: Continuous lumbar extradural analgesia
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no extradural analgesia)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Induction of extradural block
Number of subjects: 64
Study: 31471833

Group type: EXPERIMENTAL
Intervention: Substance abuse (Tobacco, Alcohol, Psychotropic Drugs)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Parental control and regulations
Number of subjects: 1000
Study: 31867913

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Catgut embedding
Number of subjects: 90

Group type: COMPARATOR
Intervention: Education group
Number of subjects: 90
Study: 28641363

Group type: EXPERIMENTAL
Intervention: OXN PR (up to 160/80 mg daily)
Number of subjects: 243

Group type: COMPARATOR
Intervention: OxyPR
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: OXN PR
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: OXN PR and OxyPR
Number of subjects: 243
Study: 26071192

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 23660099

Group type: EXPERIMENTAL
Intervention: Bifidobacterium added enteral nutrition (P+EN)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Parenteral nutrition (PN)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: All groups (P+EN, EN, PN)
Number of subjects: 70
Study: 22072411

Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 86
Study: 18164644

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Motor control exercise
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: General exercise program
Number of subjects: 191

Group type: COMPARATOR
Intervention: Pre-treatment stiffness
Number of subjects: 191
Study: 17704850

Group type: EXPERIMENTAL
Intervention: Recreational swimming combined with asthma education (twice a week for 1 hour over 6 months)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Low doses of inhaled corticosteroids (ICS) and short-acting beta2 agonists (salbutamol as needed)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Comparison of Group A and Group B at study end
Number of subjects: 65
Study: 15078472

Group type: EXPERIMENTAL
Intervention: Famciclovir followed by interferon-alpha-2a
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lamivudine followed by interferon-alpha-2a
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sequential therapy (famciclovir or lamivudine + interferon-alpha-2a)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: G1896A mutation subgroup
Number of subjects: 14
Study: 11204308

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitor (fosinopril) and a statin (pravastatin)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Diuretic and lipid‐lowering diet
Number of subjects: 508
Study: 9741405

Group type: EXPERIMENTAL
Intervention: Low dose weekly methotrexate (MTX) therapy (7.5‐12.5 mg/week)
Number of subjects: 6
Study: 9768798

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg during sevoflurane anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg during isoflurane anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg during propofol anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of sevoflurane with isoflurane and propofol anesthesia
Number of subjects: 0
Study: 2173470

Group type: EXPERIMENTAL
Intervention: Epstein-Barr virus (EBV)-specific transfer factor (TF)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 655204

Group type: EXPERIMENTAL
Intervention: Experimental pair (1 EMR student and 1 nonretarded student)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control pair (2 nonretarded students)
Number of subjects: 304
Study: 31397769

Group type: EXPERIMENTAL
Intervention: Rehab‐EMF (exercise rehabilitation)
Number of subjects: 22

Group type: COMPARATOR
Intervention: C‐EMF (control group)
Number of subjects: 22
Study: 25521867

Group type: EXPERIMENTAL
Intervention: Water jets intervention in 9 schools
Number of subjects: 2899

Group type: COMPARATOR
Intervention: Control group (10 schools that did not receive water jets)
Number of subjects: 2899
Study: 23370417

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1.25 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Natural history (control)
Number of subjects: 25
Study: 20691631

Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 90
Study: 19499738

Group type: EXPERIMENTAL
Intervention: Spirulina supplement (10 grams per day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 17532088

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine and vitamins A-E, biotin, selenium, zinc, manganese, copper, magnesium, folic acid, Coenzyme Q for 6 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 15213559

Group type: EXPERIMENTAL
Intervention: nelfinavir
Number of subjects: 38

Group type: COMPARATOR
Intervention: nevirapine
Number of subjects: 38
Study: 11246298

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (hemoglobin concentration of 70 g/L, maintained between 70 and 90 g/L)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Liberal transfusion strategy (hemoglobin concentration of 100 g/L, maintained between 100 and 120 g/L)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Both groups (restrictive and liberal)
Number of subjects: 357
Study: 9731088

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Sustained-release dexfenfluramine
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Combined dexfenfluramine groups
Number of subjects: 1072

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1072
Study: 8048734

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 3349001

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (15 mmol magnesium‐aspartate‐hydrochloride per day)
Number of subjects: 568

Group type: COMPARATOR
Intervention: Placebo (aspartic acid)
Number of subjects: 568
Study: 31929202

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Phosphoric acid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diamond bur
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diamond bur + phosphoric acid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Laser
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Laser + phosphoric acid
Number of subjects: 12
Study: 31096934

Group type: EXPERIMENTAL
Intervention: blended cognitive behaviour therapy (bCBT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: care as usual (CAU)
Number of subjects: 88
Study: 28336568

Group type: EXPERIMENTAL
Intervention: Cholinergic enhancement with donepezil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dopaminergic enhancement with bromocriptine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noradrenergic enhancement with guanfacine
Number of subjects: 0
Study: 25426659

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES-ER, Endeavor Resolute)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES, Xience V)
Number of subjects: 154
Study: 23269536

Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphisms (SNPs) associated with PSA levels from the first stage of sample (N=1,999) confirmed in the second stage (N=1,496).
Number of subjects: 3495

Group type: EXPERIMENTAL
Intervention: Genetic variants identified in the study.
Number of subjects: 3495

Group type: EXPERIMENTAL
Intervention: Personalized PSA cutoff values based on associated SNPs.
Number of subjects: 3495
Study: 21881323

Group type: EXPERIMENTAL
Intervention: hANP infusion in CKD patients (Group C)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo in CKD patients (Group A)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: hANP infusion in non-CKD patients (Group D)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo in non-CKD patients (Group B)
Number of subjects: 134
Study: 19826386

Group type: EXPERIMENTAL
Intervention: Bimatoprost in study eye (1 eye)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Latanoprost in control eye (fellow eye)
Number of subjects: 105
Study: 16951539

Group type: EXPERIMENTAL
Intervention: Pravastatin use
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control (not using pravastatin)
Number of subjects: 263
Study: 11173169

Group type: EXPERIMENTAL
Intervention: Weekly urine testing (n=16)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Monthly urine testing (n=18)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Random Drawing control (n=19)
Number of subjects: 53
Study: 9430866

Group type: EXPERIMENTAL
Intervention: Vancomycin 1000 mg administered during the last hour of CT haemodialysis
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vancomycin 1000 mg administered after dialysis
Number of subjects: 8
Study: 8238160

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (ampicillin or erythromycin)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study: 2862924

Group type: EXPERIMENTAL
Intervention: Clorazepate (an anxiolytic)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30765398

Group type: EXPERIMENTAL
Intervention: Early stimulation group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Late stimulation group (control group)
Number of subjects: 60
Study: 28779478

Group type: EXPERIMENTAL
Intervention: High-sugar milkshake
Number of subjects: 133

Group type: COMPARATOR
Intervention: High-fat milkshake
Number of subjects: 133

Group type: COMPARATOR
Intervention: Calorie-free, tasteless control solution
Number of subjects: 133
Study: 27236889

Group type: EXPERIMENTAL
Intervention: Qingfei Quyu Decoction (QQD), one dose per day for 8 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no QQD)
Number of subjects: 120
Study: 24799484

Group type: COMPARATOR
Intervention: CVI FU (225 mg/m2, 5 days per week)
Number of subjects: 1608

Group type: COMPARATOR
Intervention: Capecitabine (825 mg/m2, twice per day, 5 days per week)
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: CVI FU with oxaliplatin (50 mg/m2 once per week for 5 weeks)
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: Capecitabine with oxaliplatin (50 mg/m2 once per week for 5 weeks)
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: Oxaliplatin (50 mg/m2 once per week for 5 weeks)
Number of subjects: 1608
Study: 22906130

Group type: EXPERIMENTAL
Intervention: AZD6482 (1 μm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZD6482 (2.3 μm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZD6482 (27 μm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZD6482 (5.3 μm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZD6482
Number of subjects: 0
Study: 20332506

Group type: EXPERIMENTAL
Intervention: Facilitated advance care planning
Number of subjects: 309

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 309
Study: 17483955

Group type: EXPERIMENTAL
Intervention: MRI per OS with 6% mannitol solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: MRE with nasojejunal intubation and polyethylenglycol solution
Number of subjects: 40
Study: 15706336

Group type: EXPERIMENTAL
Intervention: Computer-aided design body jacket
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional body jacket
Number of subjects: 30
Study: 12499885

Group type: EXPERIMENTAL
Intervention: Stop group (STOP) - 10 mg prednisolone stopped after day 7 posttransplantation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Tapering group (TAP) - Gradually wean off steroids in 3 to 6 months
Number of subjects: 62
Study: 9585276

Group type: EXPERIMENTAL
Intervention: Morphine continuous intravenous infusion after a loading dose of 0.05 mg/kg, aiming for a steady-state concentration of 20 ng/mL.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Morphine continuous intravenous infusion after a loading dose of 0.05 mg/kg.
Number of subjects: 26
Study: 7636320

Group type: EXPERIMENTAL
Intervention: Hyperthermia (water temperature 39.5 degrees C) for 2 hours
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Indomethacin in hyperthermic conditions
Number of subjects: 8

Group type: COMPARATOR
Intervention: Indomethacin in thermoneutral conditions (34.5 degrees C)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Indomethacin in both hyperthermic and control experiments
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (thermoneutral water at 34.5 degrees C) for 2 hours
Number of subjects: 8
Study: 2664258

Group type: EXPERIMENTAL
Intervention: Roxithromycin (RU) 300 mg daily for 3 to 7 days
Number of subjects: 270

Group type: COMPARATOR
Intervention: Josamycin (JM) 1200 mg daily for 3 to 7 days
Number of subjects: 270
Study: 401529

Group type: EXPERIMENTAL
Intervention: Tissue valves (homografts)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Starr‐Edwards prosthetic valves
Number of subjects: 99
Study: 31679677

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Percutaneous surgery
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 34
Study: 26479144

Group type: EXPERIMENTAL
Intervention: Ischemia-tolerant mesenchymal stem cells (MSCs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25585664

Group type: EXPERIMENTAL
Intervention: etravirine plus darunavir/ritonavir (DRV group)
Number of subjects: 1115

Group type: COMPARATOR
Intervention: etravirine plus an alternative boosted protease inhibitor (other PI group)
Number of subjects: 1115
Study: 23850111

Group type: EXPERIMENTAL
Intervention: Intervention program including physical exercise, recreational activities, and nutritional counseling for 12 weeks (three times weekly)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study: 21831277

Group type: EXPERIMENTAL
Intervention: Monthly health education workshops alone (Group 1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Monthly health education workshops combined with family orientation through home visits (Group 2)
Number of subjects: 28
Study: 19027962

Group type: EXPERIMENTAL
Intervention: 20-Hz rTMS
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 22
Study: 17069496

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) for 10 sessions per day excluding weekends
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo laser treatment
Number of subjects: 39
Study: 15312405

Group type: EXPERIMENTAL
Intervention: Slow-released-gliclazide
Number of subjects: 159

Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 159
Study: 10930801

Group type: EXPERIMENTAL
Intervention: Video information cassette
Number of subjects: 220

Group type: COMPARATOR
Intervention: Non-video group (control)
Number of subjects: 220
Study: 9007680

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg (B)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Partial compliance (C)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Single dose (D)
Number of subjects: 16
Study: 8497632

Group type: EXPERIMENTAL
Intervention: Digitized images
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional film images
Number of subjects: 108
Study: 3433917

Group type: EXPERIMENTAL
Intervention: RA 27/3 rubella vaccine
Number of subjects: 631

Group type: COMPARATOR
Intervention: Control group (not immunized)
Number of subjects: 631
Study: 30920255

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Bupropion (BUP)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 95

Group type: COMPARATOR
Intervention: Delayed Quit Group (DQG)
Number of subjects: 95
Study: 30144037

Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alemtuzumab 24 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 0
Study: 26556571

Group type: EXPERIMENTAL
Intervention: 0.1% octenidine mouthrinse (Octenidol®)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthrinse (Paroex®)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse (Listerine®)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 16
Study: 24511232

Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable (RLAI)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 203

Group type: COMPARATOR
Intervention: Routine treatment group
Number of subjects: 203

Group type: COMPARATOR
Intervention: Independent sample
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Initial assessment
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Reanalysis of data
Number of subjects: 203
Study: 22324516

Group type: EXPERIMENTAL
Intervention: Levetiracetam extended-release (XR)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 20080036

Group type: EXPERIMENTAL
Intervention: Risperidone (2-6 mg/day)
Number of subjects: 628
Study: 17907484

Group type: EXPERIMENTAL
Intervention: Sodium hexametaphosphate containing dual‐phase dentifrice (Crest Vivid White)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Marketed negative control (Colgate Cavity Protection)
Number of subjects: 200
Study: 15327939

Group type: EXPERIMENTAL
Intervention: Character‐line Bisection Task (CLBT)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Letter‐line Bisection Task
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Star‐line Bisection Task
Number of subjects: 161

Group type: COMPARATOR
Intervention: Standard solid‐line bisection
Number of subjects: 161

Group type: COMPARATOR
Intervention: Line cancellation
Number of subjects: 161

Group type: COMPARATOR
Intervention: Star Cancellation
Number of subjects: 161

Group type: COMPARATOR
Intervention: Figure copying
Number of subjects: 161
Study: 11559968

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BD)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) and Beclomethasone dipropionate (BD)
Number of subjects: 77
Study: 9241288

Group type: COMPARATOR
Intervention: TRH bolus (400 micrograms)
Number of subjects: 32

Group type: COMPARATOR
Intervention: TRH infusion (400 micrograms)
Number of subjects: 32

Group type: COMPARATOR
Intervention: TRH (400 micrograms)
Number of subjects: 32
Study: 8487062

Group type: EXPERIMENTAL
Intervention: Use of the word 'cancer' vs. 'illness'
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Self-report vs. interview
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Ambiguous instructions vs. consistent instructions
Number of subjects: 165

Group type: COMPARATOR
Intervention: General medical and surgical patients
Number of subjects: 165